Wellesley, MA, United States of America

Xi-Tao Wang

This inventor holds 20 USPTO granted patents and 10 published patent applications and 2 EPO patents, primarily in Cancer Immunotherapy. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xi-Tao Wang. Retrieved from https://idiyas.com/inventor/xi-tao-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.1

ph-index = 14

Forward Citations = 408(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-IDO Antibody
OX-40 Antibodies
GITR Antibodies
Cancer Diagnostics
Immunotherapy
PD-1
PD-L1
Cancer Treatment
Tumor Immunology
Therapeutic Antibodies
Signal Disruption
Cancer Therapy
20 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Xi-Tao Wang in Antibody Development**

Introduction

Xi-Tao Wang, based in Wellesley, MA, has made significant strides in the field of biotechnology, particularly in the development of therapeutic antibodies. With a portfolio of 20 patents, Wang has contributed to innovative solutions that address critical health challenges, particularly in cancer treatment.

Latest Patents

Wang's recent patents highlight his expertise and innovation in antibody technology. One of his notable patents is for an **Anti-IDO antibody and uses thereof**, which provides antibodies that specifically bind to human IDO, along with methods for detecting IDO in biological samples. This advancement holds potential for improving diagnostic capabilities and therapeutic strategies. Another significant patent is focused on **Antibodies against OX-40 and uses thereof**. This patent encompasses antibodies that bind to the OX40 protein, with applications in treating cancer. It also includes details about the cells that produce these antibodies and the polynucleotides that encode them, demonstrating Wang’s comprehensive approach to biopharmaceutical development.

Career Highlights

Xi-Tao Wang currently works at Bristol-Myers Squibb Company, a global leader in biopharmaceuticals. At this prestigious institution, he has been able to leverage his research and innovation skills to develop cutting-edge therapeutic options. His career is marked by a commitment to advancing cancer treatment through the application of novel antibody technologies.

Collaborations

Throughout his career, Wang has collaborated with notable colleagues, including John P. Cogswell and Stacie M. Goldberg. These collaborations have played a vital role in enhancing the scope and impact of his research, fostering a collaborative environment that drives innovation in the field.

Conclusion

Xi-Tao Wang stands out as a prominent figure in biopharmaceutical innovation, with a focus on antibodies that address significant health issues like cancer. His contributions through multiple patents and collaborations reflect his dedication to advancing medical science and improving patient care. Wang's work continues to be a source of inspiration for emerging scientists and inventors in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…